Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)-Reference-Cited by-同舟云学术

Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)

Published:2012-03-26 Issue:9 Volume:26 Page:2096-2102
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Hanfstein B, ,Müller M C,Hehlmann R,Erben P,Lauseker M,Fabarius A,Schnittger S,Haferlach C,Göhring G,Proetel U,Kolb H-J,Krause S W,Hofmann W-K,Schubert J,Einsele H,Dengler J,Hänel M,Falge C,Kanz L,Neubauer A,Kneba M,Stegelmann F,Pfreundschuh M,Waller C F,Branford S,Hughes T P,Spiekermann K,Baerlocher G M,Pfirrmann M,Hasford J,Saußele S,Hochhaus A

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/leu201285.pdf

Reference32 articles.

1. Hehlmann R, Hochhaus A, Baccarani M . Chronic myeloid leukaemia. Lancet 2007; 370: 342–350.

2. O'Brien S, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348: 994–1004.

3. Deininger M, O'Brien SG, Guilhot F, Goldman JM, Hochhaus A, Hughes TP et al. International Randomized Study of Interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. Blood, ASH Annual Meeting Abstracts 2009; 114: 1126.

4. Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009; 27: 6041–6051.

5. Cortes J, Hochhaus A, Hughes T, Front-Line Kantarjian H . and Salvage Therapies With Tyrosine Kinase Inhibitors and Other Treatments in Chronic Myeloid Leukemia. J Clin Oncol 2011; 29: 524–531.

Cited by 364 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. DEEP MOLECULAR RESPONSE RATE IN CHRONIC PHASE CHRONIC MYELOID LEUKEMIA: ELEGIBILITY TO DISCONTINUATION RELATED TO TIME TO RESPONSE AND DIFFERENT FRONTLINE TKI IN THE EXPERIENCE OF THE GIMEMA LABNET CML NATIONAL NETWORK;Clinical Lymphoma Myeloma and Leukemia;2024-09

2. Exploring treatment decision-making in chronic myeloid leukemia in chronic phase;Frontiers in Oncology;2024-07-01

3. The Contemporary Role of Hematopoietic Stem Cell Transplantation in the Management of Chronic Myeloid Leukemia: Is It the Same in All Settings?;Cancers;2024-02-12

4. Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology;Journal of the National Comprehensive Cancer Network;2024-02

5. Precision medicine-based cancer care;Comprehensive Precision Medicine;2024